Optimal Blood Glucose Target in Necrotizing Fasciitis
Target blood glucose of 140-180 mg/dL (7.8-10.0 mmol/L) using a protocolized insulin infusion approach, with insulin initiation when two consecutive measurements are ≥180 mg/dL.
Rationale and Evidence Base
Patients with necrotizing fasciitis typically present with severe sepsis or septic shock, placing them in the critically ill category where glycemic management directly impacts outcomes. The Surviving Sepsis Campaign guidelines specifically recommend commencing insulin when 2 consecutive blood glucose levels are ≥180 mg/dL, targeting an upper limit ≤180 mg/dL rather than the more aggressive ≤110 mg/dL target 1. This recommendation is reinforced by the 2022 Endocrine Society guidelines for hospitalized patients in non-critical care settings, which suggest maintaining glucose targets of 100-180 mg/dL 2.
The most recent comprehensive guideline (2025) for critically ill adults explicitly states that the recommended target range for blood glucose in critically ill adults is 140-180 mg/dL (7.8-10.0 mmol/L) in most cases 3. This represents the current standard of care based on high-quality evidence.
Why This Target Range?
The evidence strongly demonstrates that tighter glycemic control (80-110 mg/dL) provides no mortality benefit and significantly increases hypoglycemia risk. A 2017 network meta-analysis of 18,098 critically ill patients found no significant differences in mortality or infection risk among four blood glucose ranges, but target concentrations <110 and 110-144 mg/dL were associated with a four to ninefold increase in hypoglycemia compared with 144-180 mg/dL 4. Hypoglycemia itself carries substantial mortality risk in critically ill patients, making the 140-180 mg/dL target the optimal balance between glycemic control and safety.
Special Considerations in Necrotizing Fasciitis
Patients with necrotizing fasciitis present unique challenges:
Diabetic patients with necrotizing fasciitis tend to present atypically with less obvious clinical signs, leading to delayed diagnosis and worse outcomes including higher amputation rates 5. However, mortality rates are comparable between diabetic and non-diabetic patients when appropriately managed.
Hyperglycemia is a prognostic marker: Research specifically examining necrotizing fasciitis found that low blood glucose levels at presentation were paradoxically associated with mortality (p=0.012), while elevated glucose (223.6 vs 154.9 mg/dL) was associated with confirmed necrosis 6, 7. This suggests that severe metabolic derangement in either direction indicates worse disease severity.
Renal impairment is common in diabetic patients with necrotizing fasciitis and affects both glucose metabolism and insulin clearance 5.
Implementation Algorithm
Step 1: Initial Assessment
- Measure point-of-care blood glucose immediately upon presentation
- If BG >180 mg/dL on two consecutive measurements, initiate insulin therapy
- Monitor glucose every 1-2 hours until stable, then every 4 hours 1
Step 2: Insulin Initiation
- Use continuous intravenous insulin infusion for critically ill patients with necrotizing fasciitis
- Target range: 140-180 mg/dL (7.8-10.0 mmol/L)
- Avoid targets <140 mg/dL due to hypoglycemia risk without mortality benefit
Step 3: Monitoring
- Use arterial blood samples when possible, as point-of-care capillary measurements may be inaccurate in shock states 1
- Watch for hypoglycemia (BG <70 mg/dL), which requires immediate treatment with 10-20 g hypertonic dextrose 8
- Continue intensive monitoring throughout surgical debridements and critical illness phase
Step 4: Transition
- Once hemodynamically stable and no longer critically ill, transition to scheduled subcutaneous insulin regimen
- Maintain target of 100-180 mg/dL for non-critical care settings 2
Critical Pitfalls to Avoid
Do not pursue aggressive glycemic targets (<110 mg/dL) in these critically ill patients. The landmark NICE-SUGAR trial definitively showed that intensive glycemic control (80-110 mg/dL) resulted in 10-15 fold higher hypoglycemia rates and slightly but significantly higher mortality (27.5% vs 25%) compared to moderate targets (140-180 mg/dL) 3.
Do not rely solely on point-of-care glucose testing in patients with shock or severe peripheral hypoperfusion, as these measurements may not accurately reflect arterial glucose values 1.
Do not delay surgical debridement to optimize glucose control—surgical intervention remains the primary therapeutic modality and takes precedence 9, 10. Glycemic management is an important adjunct but not a substitute for definitive surgical treatment.
Monitor for hypoglycemia aggressively, particularly during the perioperative period when patients may be NPO and during the post-debridement phase when metabolic demands are changing. Treat any glucose <70 mg/dL immediately 8.